Aytu BioPharma (AYTU) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

AYTU Aytu BioPharma

Watchlist

2.2600
+0.0200+0.89%

Close Oct 14 16:00 ET

2.2600
0.00000.00%

Post 16:00 ET

13.90MMarket Cap-790P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Aytu BioPharma to Participate in the 2024 Maxim Healthcare Virtual Summit
Accesswire16:15 ET
Aytu BioPharma Enters Exclusive Commercialization Agreement With Lupin
TipRanksOct 1 08:55 ET
Express News | Aytu Biopharma Inc: Lupin to Seek Local Regulatory Approvals & Marketing Authorizations for Adzenys Xr-Odt & Cotempla Xr-Over Next 18 to 24 Months.
ReutersOct 1 08:09 ET
Aytu BioPharma Announces Exclusive Agreement With Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Canada
AccesswireOct 1 08:00 ET
Aytu BioPharma Full Year 2024 Earnings: EPS Misses Expectations
Yahoo FinanceSep 28 08:49 ET
Maxim Group Maintains Aytu BioPharma(AYTU.US) With Buy Rating, Maintains Target Price $8
Moomoo NewsSep 28 08:32 ET · Ratings

Comments

Jaguar8

Oct 1 07:11

NEWS

$Aytu BioPharma (AYTU.US)$
Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Canada
Once approved by Health Canada, Adzenys and Cotempla will be the only orally disintegrating, extended-release tablets for the treatment of ADHD commercialized in Canada
DENVER, CO / ACCESSWIRE / October 1, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing ...